









Markets
/
Stocks
/
nasdaq-acon
/

Aclarion Inc

ACON

7.500USD

-0.330-4.21%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

4.37MMarket Cap

LossP/E TTM



Aclarion Inc

7.500

-0.330-4.21%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aclarion Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aclarion Inc's Score

Industry at a Glance

Industry Ranking

202 / 407

Overall Ranking

352 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

20.000

Target Price

+155.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Aclarion Inc Highlights

StrengthsRisks

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.

Growing

The company is in a growing phase, with the latest annual income totaling USD 45.72K.

Overvalued

The company’s latest PE is -0.00, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 10.19K shares, increasing 42.18% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 6.78K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.96, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 19.32K, representing a year-over-year increase of 76.09%, while its net profit experienced a year-over-year increase of 29.29%.

Score

Industry at a Glance

Previous score

6.96

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Aclarion Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.52, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.00, which is -42.86% below the recent high of -0.00 and -60521.43% above the recent low of -1.70.

Score

Industry at a Glance

Previous score

6.52

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 202/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for Aclarion Inc is 20.00, with a high of 20.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

20.000

Target Price

+155.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Aclarion Inc

ACON

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 1.01, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 10.66 and the support level at 5.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.01

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.138

Sell

RSI(14)

43.975

Neutral

STOCH(KDJ)(9,3,3)

56.716

Neutral

ATR(14)

0.413

Low Volatility

CCI(14)

-71.224

Neutral

Williams %R

78.818

Sell

TRIX(12,20)

-0.186

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

7.740

Sell

MA10

7.670

Sell

MA20

8.157

Sell

MA50

7.818

Sell

MA100

7.566

Sell

MA200

37.516

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 1.63%, representing a quarter-over-quarter increase of 2416.80%. The largest institutional shareholder is The Vanguard, holding a total of 6.78K shares, representing 1.05% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

1.71K

Geode Capital Management, L.L.C.

1.59K

+62.37%

UBS Financial Services, Inc.

1.73K

+3225.00%

Tower Research Capital LLC

75.00

+2400.00%

Thramann (Jeffrey John)

10.00

BofA Global Research (US)

8.00

+100.00%

Clear Street LLC

3.00

Ness (Brent)

3.00

Neal (David K)

2.00

Wesemann (William G)

1.00

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.30, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.42. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.